The immuno-oncology startup, formed after its Celgene-backed predecessor Flexus was bought for $1.25bn last year, has revealed $79m of financing across two rounds.
US-based cancer immunotherapy developer FLX Bio raised $50m on Tuesday in a series B round that included pharmaceutical company Celgene.
Venture capital firms The Column Group (TCG) and Kleiner Perkins Caufield & Byers (KPCB) also participated in the round, as did private equity firm Topspin Partners.
FLX is developing oral immuno-oncology medicines, and was formed when its predecessor company, Flexus Biosciences, was acquired by biopharmaceutical company Bristol-Myers Squibb for $1.25bn in February 2015. Celgene, TCG and KPCB were also…